PPT-Raltegravir for

Author : min-jolicoeur | Published Date : 2017-05-20

t he p revention o f mother tochild t ransmission o f HIV MJ Trahan V Lamarre ME Metras N Lapointe F Kakkar Centre Hospitalier Universitaire Sainte Justine

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Raltegravir for" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Raltegravir for: Transcript

t he p revention o f mother tochild t ransmission o f HIV MJ Trahan V Lamarre ME Metras N Lapointe F Kakkar Centre Hospitalier Universitaire Sainte Justine Université. TUAA0301. Pre-clinical Evaluation of HIV Replication Inhibitors that Target the HIV . Integrase. -LEDGF/p75 Interaction . Frauke . Christ. , Chris Pickford, Jonas Demeulemeester, Stephen Shaw, Belete Desiemmie, Caroline Smith-Burchnell, Scott Butler, Mike Westby, Zeger Debyser. QDMRK. SPRING-2. ONCEMRK. ONCEMRK. Design. Objective. Non inferiority of RAL QD: % HIV RNA < 40 c/mL by ITT, NC=F . (lower margin of the 2-sided 95% CI for the difference = - 10%, 90% power). RAL 1200 mg ** QD + . ART . on . IRIS . in the . REALITY . trial. Diana M Gibb . on behalf of. the . REALITY . trial team. Background. The Reality trial, in adults/children . with CD4<100 . cells/µl . initiating ART in sub-Saharan Africa, . SPRING-2 Study. Dolutegravir. versus Raltegravir. SPRING-2: Design. Source: . Raffi. F, et al. Lancet. 2013;381:735-43.. Dolutegravir. : 50 mg QD. Fixed-dose NRTI backbone*. (n = 411). Raltegravir. R. itonavir to Raltegravir. SWITCHMRK 1 & 2 Trials. Switching from Lopinavir-Ritonavir to Raltegravir. SWITCHMRK 1 & 2 Trials: Study Design. Source: . Eron. JJ, et al. Lancet. 2010;375:396-407.. RADAR Trial. Raltegravir. + Darunavir/r versus TDF-FTC + Darunavir/r. RADAR: Study Design. Source: . Bedimo. RJ, et al. . PLoS. One. 2014;9:e106221.. Darunavir QD + Ritonavir QD + Raltegravir BID . NEAT001/ANRS 143 Trial. Darunavir/r + Raltegravir versus Darunavir/r + TDF-FTC. NEAT001/ANRS143: Study Design. Source: . Raffi. F, et al. Lancet. 2014;384:1942-51. .. Darunavir + Ritonavir QD. + Raltegravir BID .

Download Document

Here is the link to download the presentation.
"Raltegravir for"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.